Both companies aim to improve the efficiency and success rate of the current drug discovery process.
Filing for WHO Emergency Use Authorisation this month
The transaction is expected to close in the Q4FY22
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
Advances deployment of mRNA technology across vaccines and therapeutics development
Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread
Deal for 100 million doses with additional 100 million through 2023
Reinforcing position as a premier provider of end-to-end research intelligence solutions for Life Sciences
AstraZeneca, Sinopharm and Moderna were part of the study
Arrow is the marketing partner in US
Subscribe To Our Newsletter & Stay Updated
